ADIL - CIK 0001513525
The table below shows ADIAL PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.61M | -$1.59M | -$1.63M | -$2.30M | -$2.50M | -$2.84M |
| Capital expenditure | - | - | - | - | - | $30.88K |
| Investing cash flow | - | $150.00K | - | - | - | -$286.00 |
| Dividends paid | - | - | - | - | - |
ADIAL PHARMACEUTICALS, INC. reported operating cash flow of -$6.49M for fiscal year 2025. That is up 6.2% from -$6.92M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$494.86K (FY 2017) to -$6.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $315.28K | $50.65K | $3.82M | $609.61K | $9.12M | $4.08M |